Oral and Maxillofacial Tumor Management - From Biopsy to Surgical Removal

Castejón-González, Ana C.; Reiter, Alexander M.

doi:10.1016/j.cvsm.2021.09.005

Cited by 2 publications

(5 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously reported, reconstruction of facial defect using deltopectoral flap was validated to be feasible [ 5 ]. Other cases of OMF tumors achieved temporary control by removing infection and the source of pain so as to keep masticatory function and improve the life quality of patients [ 6 ]. For example, the use of diode laser ablation produced outstanding esthetic and functional outcomes during a 6-month follow-up period [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

FOXD2-AS1 promotes malignant cell behavior in oral squamous cell carcinoma via the miR-378 g/CRABP2 axis

Guo,

Huang,

You

et al. 2024

BMC Oral Health

View full text Add to dashboard Cite

Background Oral squamous cell cancer (OSCC) is a prevalent malignancy in oral cavity, accounting for nearly 90% of oral malignancies. It ranks sixth among the most common types of cancer worldwide and is responsible for approximately 145,000 deaths each year. It is widely accepted that noncoding RNAs participate cancer development in competitive regulatory interaction, knowing as competing endogenous RNA (ceRNA) network, whereby long non-coding RNA (lncRNA) function as decoys of microRNAs to regulate gene expression. LncRNA FOXD2-AS1 was reported to exert an oncogenic role in OSCC. Nevertheless, the ceRNA network mediated by FOXD2-AS1 was not investigated yet. This study aimed to explore the effect of FOXD2-AS1 on OSCC cell process and the underlying ceRNA mechanism. Methods FOXD2-AS1 expression in OSCC cells were determined via reverse transcription and quantitative polymerase chain reaction. Short hairpin RNA targeting FOXD2-AS1 was transfected into OSCC cells to silence FOXD2-AS1 expression. Then, loss-of-function experiments (n = 3 each assay) were performed to measure cell proliferation, apoptosis, migration, and invasion using colony formation, TdT-mediated dUTP Nick-End Labeling, wound healing and Transwell assays, respectively. RNA binding relation was verified by RNA immunoprecipitation and luciferase reporter assays. Rescue experiments were designed to validate whether FOXD2-AS1 affects cell behavior via the gene cellular retinoic acid binding protein 2 (CRABP2). Statistics were processed by GraphPad Prism 6.0 Software and SPSS software. Results FOXD2-AS1 was significantly upregulated in Cal27 and SCC9 cells (6.8 and 6.4 folds). In response to FOXD2-AS1 knockout, OSCC cell proliferation, migration and invasion were suppressed (approximately 50% decrease) while OSCC cell apoptosis was enhanced (more than two-fold increase). FOXD2-AS1 interacted with miR-378 g to alter CRABP2 expression. CRABP2 upregulation partly rescued (*p < 0.05, **p < 0.01, ***p < 0.001) the inhibitory impact of FOXD2-AS1 depletion on malignant characteristics of OSCC cells. Conclusion FOXD2-AS1 enhances OSCC malignant cell behaviors by interacting with miR-378 g to regulate CRABP2 expression.

show abstract

Section: Introductionmentioning

confidence: 99%

FOXD2-AS1 promotes malignant cell behavior in oral squamous cell carcinoma via the miR-378 g/CRABP2 axis

Guo,

Huang,

You

et al. 2024

BMC Oral Health

View full text Add to dashboard Cite

show abstract

“…If necessary, these vessels would be ligated and transected. 7 The indications for a segmental (central) maxillectomy include: benign and malignant neoplasms, osteonecrosis, osteomyelitis, and less commonly, severely comminuted fractures. 5 The primary objective of oral oncologic surgery is to achieve a surgical cure while maintaining occlusion, or in some cases to achieve local control of a malignant neoplasm.…”

Section: Introductionmentioning

confidence: 99%

“…5 The primary objective of oral oncologic surgery is to achieve a surgical cure while maintaining occlusion, or in some cases to achieve local control of a malignant neoplasm. 7 If indicated, based on tumor type, staging of the patient should be done prior to oral oncologic surgery. 7 Surgical planning and consultation with an oncologist should also be completed prior to the resective surgery.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…7 If indicated, based on tumor type, staging of the patient should be done prior to oral oncologic surgery. 7 Surgical planning and consultation with an oncologist should also be completed prior to the resective surgery. Surgical planning could make use of magnetic resonance imaging, computed tomography (CT) with or without contrast, cone beam computed tomography (CBCT) with multi-planar reconstructions, and/or digital intraoral radiographs.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Segmental (Central) Maxillectomy Using a Piezoelectric Surgery Unit in a Dog

Sasser

2023

J Vet Dent

View full text Add to dashboard Cite

Piezoelectric surgical units operate with a vibration in the range of 25 to 35 KHz, offering several advantages including high precision, selective cutting of bone while limiting damage to the surrounding soft tissues, less trauma to neurovascular tissues, reduced hemorrhage, and improved healing. Manual bone-cutting instruments operate at a high speed and can lead to thermal injury to the bone, severe damage to blood vessels, nerves, and soft tissues, and increased pain following bone surgery. This step-by-step manuscript describes the use of a piezoelectric surgical unit to perform a segmental (central) maxillectomy.

show abstract

Oral and Maxillofacial Tumor Management - From Biopsy to Surgical Removal

Cited by 2 publications

References 64 publications

FOXD2-AS1 promotes malignant cell behavior in oral squamous cell carcinoma via the miR-378 g/CRABP2 axis

FOXD2-AS1 promotes malignant cell behavior in oral squamous cell carcinoma via the miR-378 g/CRABP2 axis

Segmental (Central) Maxillectomy Using a Piezoelectric Surgery Unit in a Dog

Contact Info

Product

Resources

About